Metformin HCl

別名:1,1-Dimethylbiguanide HCl

Metformin HCl (1,1-Dimethylbiguanide HCl) decreases hyperglycemia in hepatocytes primarily by suppressing glucose production by the liver (hepatic gluconeogenesis). Metformin promotes mitophagy in mononuclear cells. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.

Metformin HCl 化学構造

CAS No. 1115-70-4

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫あり
JPY 29500 国内在庫あり
JPY 59500 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(86)

製品安全説明書

現在のバッチを見る: 純度: 99.99%
99.99

Metformin HCl と併用されることが多い化合物

Glyburide (Glibenclamide)


Metformin HCl and Glyburide are used in the treatment of type 2 diabetes mellitus.

Melatonin


Metformin HCl and Melatonin are effective in reduction of plasmatic levels of liver enzymes and decrease inflammatory response in rats.

Lemos AJJM, et al. Toxicol Appl Pharmacol. 2014 Oct 1;280(1):159-68.

Repaglinide


Metformin HCl and Repaglinide result in a reduction in glycated hemoglobin (HbA1c).

Kawamori R, et al. J Diabetes Investig. 2014 Feb 12;5(1):72-9.

Ertugliflozin


Metformin HCl and Ertugliflozin are used for the treatment of type 2 diabetes.

Frias JP, et al. Expert Rev Endocrinol Metab. 2019 Mar;14(2):75-83.

Etoposide


Metformin HCl and Etoposide increase mortality in B-CPAP and SW-1736 cells and reduce toxicity of these drugs in the normal cell lines.

Ghavami G, et al. Res Pharm Sci. 2023 Jan 19;18(2):185-201.

Metformin HCl 関連製品

Carbohydrate Metabolism阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
human MDA-MB-231 cells Function assay 1 to 20 mM 24 h Antiproliferative activity against human MDA-MB-231 cells at 1 to 20 mM after 24 hrs by MTT assay. 22459208
human HepG2 cells Function assay 1 mM 24 h Reduction of glucose consumption in insulin-resistant human HepG2 cells at 1 mM after 24 hrs by glucose oxidase method in presence of 22.2 mM of glucose 23025244
human HepG2 cells Function assay 1 mM 24 h Activation of AMPK in human HepG2 cells assessed as reduction of gluconeogenesis at 1 mM after 24 hrs by enzymatic colorimetric assay 26471090
Hs575T Function assay 20 mM 24 hrs Inhibition of mTOR phosphorylation in triple-negative human Hs575T cells at 20 mM after 24 hrs by immunoblot analysis 23490148
Hs578T Antiinvasive assay 20 mM 17 hrs Antiinvasive activity against triple-negative human Hs578T cells at 20 mM after 17 hrs by light microscopic analysis 23490148
Hs575T Function assay 20 mM 24 hrs Activation of AMPK in triple-negative human Hs575T cells at 20 mM after 24 hrs by immunoblot analysis 23490148
L6 Function assay 2 mM 4 hrs Increase in glucose uptake in rat L6 cells at 2 mM treated for 4 hrs post 30 mins AMPK inhibitor compound C treatment 29128163
HepG2 Function assay 1 mM 24 hrs Induction of glucose consumption in human HepG2 cells at 1 mM incubated for 24 hrs 28651984
mouse 3T3L1 cells Function assay 1 mM Induction of AMPK phosphorylation in mouse 3T3L1 cells at 1 mM by Western blot analysis 25216379
human HepG2 cells Function assay 24 h Increase in glucose consumption in insulin-resistant human HepG2 cells after 24 hrs, EC50=0.27 μM. 21856048
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Metformin HCl (1,1-Dimethylbiguanide HCl) decreases hyperglycemia in hepatocytes primarily by suppressing glucose production by the liver (hepatic gluconeogenesis). Metformin promotes mitophagy in mononuclear cells. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.
Targets
AMPK [1]
(Hepatocytes)
In Vitro
In vitro

Metformin (500 μM) activates AMPK in hepatocytes, as a result, acetyl-CoA carboxylase (ACC) activity is reduced, fatty acid oxidation is induced, and expression of lipogenic enzymes is suppressed. Metformin (2 mM) activates muscle AMPK and promotes glucose uptake. Metformin (500 μM) or AICAR strongly suppresses SREBP-1 mRNA expression in rat hepatocytes. Metformin ameliorates hyperglycemia without stimulating insulin secretion, promoting weight gain, or causing hypoglycemia. Metformin has beneficial effects on circulating lipids linked to increased cardiovascular risk. Metformin decreases hepatic glucose production and increases skeletal myocyte glucose uptake. [1]

Metformin requires LKB1 in the liver to lower blood glucose levels. [2]

Metformin (2 mM) leads to a significant increase in the activity of both α1- and α2-containing complexes in muscle cells. Metformin (2 mM) also increases threonine 172 phosphorylation in muscle cells. [3]

細胞実験 細胞株 Rat primary hepatocytes
濃度 500 µM
反応時間 1 h
実験の流れ

Cells were treated with different concentrations of metformin.

実験結果図 Methods Biomarkers 結果図 PMID
Western blot p-AMPK / AMPK / p-mTOR / mTOR / p-S6K / S6K TTP / p-STAT3 / STAT3 / c-Myc pACC / ACC / pS6 / S6 pSTAT3 (Ser727) / STAT3 / Jak2 / Cdk5 / pNFκB / Bcl-2 / Bcl-XL / c-Myc 24505341
Immunofluorescence LKB1 PAR CD86 / CD206 beta-catenin / AMPK 29601127
Growth inhibition assay Cell viability 26956973
In Vivo
In Vivo

Metformin (100 mg/ml, po) treatment produces significant decreases in hepatic expression of mRNAs for SREBP-1, FAS, and S14 in SD rats that are consistent with effects documented in cells. Metformin also decreases hepatic lipids in obese mice. [1]

Metformin (250 mg/kg, i.p.) increases AMPK phosphorylation in livers of wild-type mice. Metformin (250 mg/kg, i.p.) treatment reduces blood glucose by more than 50% in the wild-type mice on a high-fat diet. Metformin (250 mg/kg, i.p.) treatment also loweres blood glucose in the ob/ob mice by 40%. [2]

動物実験 動物モデル Male Sprague-Dawley rats
投与量 100 mg/300 mg
投与経路 o.g.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06147050 Not yet recruiting
Long COVID
Trust for Vaccines and Immunization Pakistan
January 2024 Phase 3
NCT06120881 Not yet recruiting
Type 2 Diabetes
University of California San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
December 1 2023 Early Phase 1
NCT06160414 Not yet recruiting
Healthy
Alexion Pharmaceuticals Inc.
December 13 2023 Phase 1
NCT05847244 Recruiting
Diastolic Dysfunction|Obesity
Sara ElAdawy|Cairo University|October University for Modern Sciences and Arts
October 1 2023 Phase 2

化学情報

分子量 165.62 化学式

C4H11N5.HCl

CAS No. 1115-70-4 SDF Download Metformin HCl SDFをダウンロードする
Smiles CN(C)C(=N)N=C(N)N.Cl
保管

In vitro
Batch:

Water : 33 mg/mL

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Metformin HCl を買う | Metformin HCl ic50 | Metformin HCl 供給者 | Metformin HCl を購入する | Metformin HCl 費用 | Metformin HCl 生産者 | オーダーMetformin HCl | Metformin HCl 化学構造 | Metformin HCl 分子量 | Metformin HCl 代理店